NCT04868708 2025-03-04A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical CancerAkesoPhase 2 Completed50 enrolled
NCT05824975 2024-11-25A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)GI Innovation, Inc.Phase 1/2 Recruiting358 enrolled